CoChat
Sign Up
Cited by 4Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Genomics and Diagnostics

The DOI matches its Crossref record, with a small difference in title or year; 4 of the 4 references it cites were found in a registry or an index.

Targeted Therapies in Non–Small Cell Lung Cancer: A Contemporary Review

Abdelmonem, Ahmed, Bikram Shah, Bidhan, Shebli, Mouza Al, Tabbara, Imad A.·2026·American Journal of Clinical Oncology
DOI 10.1097/coc.0000000000001275
Open this paper in CoChat — free account

Abstract

Lung cancer is the leading cause of cancer-related mortality worldwide, with non–small cell lung carcinoma (NSCLC) comprising over 85% of cases. Advances in molecular diagnostics and precision oncology have shifted treatment toward mutation-driven strategies, resulting in significantly improved patient outcomes. This review synthesizes current evidence on the most clinically relevant genetic alterations in NSCLC and their corresponding targeted therapies, including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 fusions, BRAF V600E mutations, MET exon 14 skipping mutations, RET and NTRK fusions, HER2 alterations, and KRAS G12C mutations. We outline mechanisms of action, clinical efficacy, and limitations of FDA-approved tyrosine kinase inhibitors (TKIs) and emerging agents, with emphasis on resistance pathways, both on-target and bypass-mediated, observed during treatment with drugs such as osimertinib, crizotinib, sotorasib, and entrectinib. The role of next-generation sequencing (NGS), liquid biopsy, and comprehensive biomarker profiling in guiding personalized therapy selection is also discussed, along with strategies for sequential therapy and rational combination approaches.

Overview

Integrity signals

Registry

Crossref · 10.1097/coc.0000000000001275

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 53

  1. Siegel, 2023, Cancer statistics, 2023, CA Cancer J Clin, 73, 17
  2. Schiller, 2024, Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer, N Engl J Med, 370, 950
  3. Lindeman, 2022, Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors, J Thorac Oncol, 17, 362
  4. Peters, 2023, Alectinib versus crizotinib in untreated ALK-positive NSCLC, N Engl J Med, 377, 829, 10.1056/NEJMoa1704795 · DOI · Paper page
  5. Mok, 2023, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674 · DOI · Paper page
  6. Paik, 2022, Tepotinib in NSCLC with MET exon 14 skipping mutations, N Engl J Med, 383, 931, 10.1056/NEJMoa2004407 · DOI
  7. Drilon, 2020, Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer, N Engl J Med, 383, 813, 10.1056/NEJMoa2005653 · DOI
  8. Skoulidis, 2023, Sotorasib for lung cancers with KRAS p.G12C mutation, N Engl J Med, 384, 2371, 10.1056/NEJMoa2103695 · DOI · Paper page
  9. Reck, 2024, Pembrolizumab versus chemotherapy for PD–L1–positive NSCLC, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  10. Rolfo, 2022, Liquid biopsy for advanced NSCLC: consensus statement from IASLC, J Thorac Oncol, 17, 839
  11. Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662 · DOI · Paper page
  12. Johnson, 2022, Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies, Lung Cancer, 170, 41, 10.1016/j.lungcan.2022.05.011 · DOI
  13. Planchard, 2023, Osimertinib with or without Chemotherapy in EGFR-mutated advanced NSCLC, N Engl J Med, 389, 1935, 10.1056/NEJMoa2306434 · DOI
  14. Lindeman, 2018, Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology, J Thorac Oncol, 13, 323, 10.1016/j.jtho.2017.12.001 · DOI
  15. Leonetti, 2019, Resistance mechanisms to osimertinib in EGFR-mutated NSCLC, Br J Cancer, 121, 725, 10.1038/s41416-019-0573-8 · DOI
  16. Cho, 2024, Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC, N Engl J Med, 391, 1486, 10.1056/NEJMoa2403614 · DOI
  17. Mok, 2009, Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 · DOI · Paper page
  18. Lu, 2024, Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC, N Engl J Med, 391, 585, 10.1056/NEJMoa2402614 · DOI
  19. Brazel, 2024, MARIPOSA: can amivantamab and lazertinib replace osimertinib in the front-line setting?, Lung Cancer (Auckl), 15, 41
  20. Herbst, 2023, Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized Adaura trial, J Clin Oncol, 41, 1830, 10.1200/JCO.22.02186 · DOI
  21. Koulouris, 2022, Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies, Cancers (Basel), 14, 3337, 10.3390/cancers14143337 · DOI
  22. Shi, 2022, Emerging strategies to overcome resistance to third-generation EGFR inhibitors, J Hematol Oncol, 15, 94, 10.1186/s13045-022-01311-6 · DOI
  23. Chen, 2023, Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review, Transl Lung Cancer Res, 12, 337, 10.21037/tlcr-22-631 · DOI
  24. Hernandez, 2023, A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma, Transl Lung Cancer Res, 12, 1549, 10.21037/tlcr-22-855 · DOI
  25. Niu, 2017, Anaplastic lymphoma kinase testing: IHC vs. FISH vs. NGS, Curr Treat Options Oncol, 18, 71, 10.1007/s11864-017-0513-x · DOI
  26. Gadgeel, 2018, Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study, Ann Oncol, 29, 2214, 10.1093/annonc/mdy405 · DOI
  27. Camidge, 2020, Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L Trial, J Clin Oncol, 38, 3592, 10.1200/JCO.20.00505 · DOI
  28. Desai, 2023, Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review, Transl Lung Cancer Res, 12, 615, 10.21037/tlcr-22-708 · DOI
  29. Gendarme, 2022, ROS-1 fusions in non-small-cell lung cancer: evidence to date, Curr Oncol, 29, 641, 10.3390/curroncol29020057 · DOI · Paper page
  30. Go, 2013, Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm, J Thorac Oncol, 8, 1445, 10.1097/JTO.0b013e3182a4dd6e · DOI
  31. Dyrbekk, 2023, Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer, Diagn Pathol, 18, 70, 10.1186/s13000-023-01357-1 · DOI
  32. Romanò, 2022, Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: no advantage of voxel dosimetry with respect to mean dose in dose-response analysis with two radiological methods, Cancers (Basel), 14, 959, 10.3390/cancers14040959 · DOI
  33. Waliany, 2024, Taletrectinib: TRUST in the continued evolution of treatments for ROS1 fusion-positive lung cancer, J Clin Oncol, 42, 2622, 10.1200/JCO.24.01062 · DOI
  34. Skoulidis, 2021, Sotorasib for lung cancers with KRAS p.G12C mutation, N Engl J Med, 384, 2371, 10.1056/NEJMoa2103695 · DOI · Paper page
  35. Miyashita, 2024, KRAS G12C inhibitor combination therapies: current evidence and challenge, Front Oncol, 14, 1380584, 10.3389/fonc.2024.1380584 · DOI
  36. Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumor immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1 · DOI · Paper page
  37. Fan, 2024, Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer, Transl Lung Cancer Res, 13, 3382, 10.21037/tlcr-24-494 · DOI
  38. O’Leary, 2019, Targeting BRAF mutations in non-small cell lung cancer, Transl Lung Cancer Res, 8, 1119, 10.21037/tlcr.2019.10.22 · DOI
  39. Hwang, 2022, Selection strategies and practical application of BRAF V600E-mutated non-small cell lung carcinoma, Cancer Res Treat, 54, 782, 10.4143/crt.2021.843 · DOI
  40. Wolf, 2020, Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer, N Engl J Med, 383, 944, 10.1056/NEJMoa2002787 · DOI
  41. Paik, 2020, Tepotinib in non-small-cell lung cancer with met Exon 14 skipping mutations, N Engl J Med, 383, 931, 10.1056/NEJMoa2004407 · DOI
  42. Drilon, 2020, Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer, N Engl J Med, 383, 813, 10.1056/NEJMoa2005653 · DOI
  43. Griesinger, 2022, Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial, Ann Oncol, 33, 1168, 10.1016/j.annonc.2022.08.002 · DOI
  44. Clifton-Bligh, 2025, Mechanisms of resistance to RET-directed therapies, Endocr Relat Cancer, 32, e240224, 10.1530/ERC-24-0224 · DOI
  45. Drilon, 2018, Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448 · DOI · Paper page
  46. Cocco, 2018, NTRK fusion-positive cancers and TRK inhibitor therapy, Nat Rev Clin Oncol, 15, 731, 10.1038/s41571-018-0113-0 · DOI
  47. Haratake, 2021, NTRK fusion-positive non-small-cell lung cancer: the diagnosis and targeted therapy, Clin Lung Cancer, 22, 1, 10.1016/j.cllc.2020.10.013 · DOI
  48. Li, 2022, Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer, N Engl J Med, 386, 241, 10.1056/NEJMoa2112431 · DOI
  49. Riudavets, 2021, Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations, ESMO Open, 6, 100260, 10.1016/j.esmoop.2021.100260 · DOI
  50. Lee, 2020, Clinical characteristics and outcomes of non-small cell lung cancer patients with HER2 alterations in Korea, Cancer Res Treat, 52, 292, 10.4143/crt.2019.186 · DOI
  51. Heymach, 2025, Zongertinib in previously treated HER2-mutant non-small-cell lung cancer, N Engl J Med, 392, 10.1056/NEJMoa2503704 · DOI · Paper page
  52. Romero, 2025, Promising results with zongertinib in advanced-stage HER2-mutant NSCLC, Nat Rev Clin Oncol, 22, 459, 10.1038/s41571-025-01030-0 · DOI
  53. Heymach, 2025, Zongertinib in previously treated HER2-mutant non-small-cell lung cancer, N Engl J Med, 392, 1623, 10.1056/NEJMoa2503704 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Abdelmonem, A., Bikram Shah, B., Shebli, M. A., & Tabbara, I. A.
Affiliations
  • George Washington University (US)
  • Division of Hematology/Oncology, Luminis Health Center for Cancer and Blood Disorders, Annapolis, MD
Corresponding author
Abdelmonem, Ahmed
ORCID
Abdelmonem, Ahmed
Venue
American Journal of Clinical Oncology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2025-12-15
Volume
49
Issue
10
Pages
510-516
ISSN
  • 0277-3732 (ISSN-L)
  • 1537-453X
DOI
10.1097/coc.0000000000001275
OpenAlex
W4417333125
Cited by
4
References
4
Citations by year
2026: 4
FWCI
0.70
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
non-small cell lung cancer, targeted therapy, tyrosine kinase inhibitors, EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, MET exon 14 skipping, RET fusion, NTRK fusion, HER2 alterations, KRAS G12C, osimertinib, crizotinib, sotorasib, entrectinib, drug resistance, next-generation sequencing, liquid biopsy, biomarker profiling, precision oncology, combination therapy
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Protein Kinase Inhibitors, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review